One week after expanding the company’s neurodegenerative diseases partnership with Bristol Myers Squibb, Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.

The U.S. government’s Medicare program on January 11 said it plans to cover Alzheimer’s treatments including Biogen Inc.’s Aduhelm, with some conditions.

Eli Lilly acquired exclusive rights to a technology from Canada-based Entos Pharmaceuticals that the Indianapolis-based company believes will boost the development of nucleic acid therapeutics that target the central and peripheral nervous systems.

Eli Lilly and Company’s projections for next year exceed Wall Street projections for the drug manufacturer, predicting 2022 revenue of $27.8 billion to $28.3 billion.

Lilly announced that mirikizumab, the company’s monoclonal antibody formulation to treat ulcerative colitis (UC), met the primary endpoint of clinical remission and all key secondary endpoints at one year in a Phase III maintenance study.

German researchers found that COVID-19 therapies developed by Eli Lilly and Regeneron lose most of their effectiveness when exposed in laboratory tests to the Omicron variant of coronavirus, likely reducing treatment options if the new variant prevails.

Loxo Oncology, part of Eli Lilly, partnered with Foghorn Therapeutics in a deal that enables the former to use the latter’s Gene Traffic Control platform to advance its pipeline of oncology medicines. 

Eli Lilly forged a multi-year collaborative partnership with China-based Regor Therapeutics Group to discover and develop new therapies for metabolic disorders.

Drugmakers have targeted the U.S. market to earn outsized profits from old medicines, according to a report released on December 10 by the House Oversight Committee that highlighted Lilly, Novo Nordisk and Sanofi, which control the market for insulin.

The U.S. health regulator added the FDA’s strictest warning to the labels of drugs from Pfizer, Eli Lilly and AbbVie belonging to a class of anti-inflammatory treatments called JAK inhibitors, citing risk of serious health issues and death in patients 50 and over, the drugmakers said on December 3.